Research & Development
Guidance for antibiotics, diagnostics use in an epidemic
In a statement published Wednesday in Infection Control & Hospital Epidemiology, SHEA provided strategies for hospitals and healthcare personnel to improve antibiotic prescribing when they encounter new infectious disease outbreaks.
September 14, 2022
DiaSorin nabs FDA clearance for infectious disease blood test
The fully automated test utilizes host response-based data to enable physicians to differentiate accurately between bacterial and viral infections, supporting faster and better-informed treatment and patient management decisions, DiaSorin said.
July 21, 2022
Inflammatix lands $12.1M in new BARDA deal
The company's third tranche of funding from BARDA is part of a contract worth up to $72 million if all options are exercised. Inflammatix said it would use the funds for ongoing development and clinical studies of its ViraBac EZ acute infection test, which determines whether a suspected infection is bacterial or viral based on gene expression patterns in the immune system.
November 18, 2021
Lumos touts cost savings for point-of-care infection test
FebriDx is a finger-stick blood test that distinguishes bacterial from viral acute respiratory infections. The study, published September 30 in the Journal of Health Economics and Outcomes Research, found that FebriDx had a sensitivity of 95% to detect bacterial infections and a negative predictive value of 99% to rule out these infections.
October 6, 2021
Inflammatix secures $102M in financing
Inflammatix's diagnostics use machine-learning algorithms to track a patient's immune response to infections across multiple messenger RNA (mRNA) biomarkers, it said. The tests identify whether an infection is viral or bacterial and help clinicians gauge the risk of severe disease, including COVID-19, producing results in less than 30 minutes, according to the firm.
March 15, 2021
Test identifies any infection from any sample in hours
Scientists from the University of California, San Francisco developed the test, which requires no special handling or processing for each specific bodily fluid and uses next-generation DNA sequencing technology. It accounts for all DNA in a single sample. The test uses a new analytical software application to compare DNA sequences in the sample to genomic databases that cover all bacterial, viral, parasitic, or fungal infections from any species.
November 10, 2020
DNA forensic evidence frees Ohio man of rape, attempted rape
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Inflammatix secures $7.4M in BARDA funding
The funding will allow the company to further develop its point-of-care test for diagnosing infection and is part of a larger BARDA contract worth up to $72 million if milestones are met, the company said.
October 28, 2020
Tangen wins contract for Candida auris point-of-care test
The C. auris test will run on the company's TangenDx platform, which includes an assay kit and the company's GeneSpark analyzer. Tangen currently markets rapid tests for bloodstream Candida infections, bacterial infections, and antimicrobial resistance. It plans to file an emergency use authorization for a point-of-care COVID-19 test with the U.S. Food and Drug Administration this summer.
June 28, 2020
Procalcitonin test signals infection in heart attack patients
As an important marker for inflammation in the body, a blood test for PCT is useful for systemic bacterial infections and sepsis. But its value for detecting infection in patients with acute ST-elevation myocardial infarction (STEMI) -- an area of unmet need -- has been unclear. One key question is whether it is specific enough for infection, or whether levels would increase due to cardiac injury -- a limitation of other inflammatory biomarkers such as C-reactive protein (CRP) and white blood cell counts.
June 15, 2020
Lumos gets cash to expand reach of respiratory test
Lumos is a Planet Innovation spin-off that merged with RPS Diagnostics in May 2019. The company plans to use the funding to support international market expansion of its FebriDx point-of-care (POC) respiratory infection test, as well as a pivotal trial to support approval of the product by the U.S. Food and Drug Administration (FDA).
February 5, 2020
Inflammatix gets $32M infusion for HostDx rapid POC tests
Based in Burlingame, CA, Inflammatix is developing blood and nasal swab tests for the detection of infections and antibiotic resistance. Its platform is informed by machine-learning algorithms and gene expression patterns to identify bacterial and viral infections, and it yields results in 30 minutes or less, according to the company.
January 9, 2020
T2 Biosystems recruits Chembio's John Sperzel as new CEO
In the statement about the appointment, T2 noted that during his tenure at Chembio, Sperzel established U.S. and international sales teams that generated significant growth, and the company also made commercial investments in Latin America and Southeast Asia. Sperzel is replacing John McDonough, who will continue to serve as nonexecutive chairman of the board.
January 8, 2020
Page 1 of 2